Expansion of the SMO business structure, facilities served and target areas
First written in FY2016. 1 of 4 entries say "Restated". Latest entry: FY2017.
No other company in this theme has enough history to compare yet.
- FY2017DroppedAnnual report
「We transferred our subsidiary engaged in the SMO business in June 2017. Going forward, we will concentrate management resources on our core business, work to create an environment in which technical employees can remain active throughout their careers, raise the level of our professional technical services, strengthen our corporate foundation over the medium to long term and enhance corporate value.」
We had been expanding the SMO business, but our efforts to expand the SMO business at the company ended with the transfer of the subsidiary. - FY2017-Q2AdvancedAnnual report
「In the SMO business, project acquisition expanded, particularly in the dermatology and psychiatry fields, and orders for peripheral SMO services also increased. However, training costs rose as a result of hiring new graduates, while the increase in global trials lengthened the time required by pharmaceutical companies to prepare for trials, resulting in delays to trial start dates.」
We recorded progress in the form of increased project acquisition, centred on the dermatology and psychiatry fields, and increased orders for peripheral SMO services. - FY2017-Q1RestatedAnnual report
「In the SMO business, the company promoted the acquisition of projects in the dermatology and psychiatry fields and worked to expand sales activities aimed at expanding adjacent SMO services.」
We continue to acquire projects in the dermatology and psychiatry fields and expand peripheral SMO services. - FY2016First statedAnnual report
「1. Development of the framework: In the Tokyo, Kanagawa and Kansai areas, we will respond to the digitisation of clinical trials, improve personnel utilisation efficiency and expand the facilities we serve. 2. Development of facilities: Alongside expanding our presence in our strong dermatology area, we will enter a broad range of areas, centred on large general hospitals and hospitals specialising in dementia.」
In the SMO business, we plan to advance the digitisation of clinical trials, improve personnel efficiency, expand covered facilities and enter areas beyond dermatology.